---
layout: post
title: "Issuance of Priority Review Voucher; Material Threat Medical Countermeasure Product; EBANGA"
date: 2026-02-04 21:51:34 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-06970
original_published: 2025-04-23 00:00:00 +0000
significance: 8.00
---

# Issuance of Priority Review Voucher; Material Threat Medical Countermeasure Product; EBANGA

**Published:** February 04, 2026 21:51 UTC
**Source:** Federal Register
**Original Published:** April 23, 2025 00:00 UTC
**Document Number:** 2025-06970

## Summary

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a material threat medical countermeasure (MCM) product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved material threat MCM product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that EBANGA (ansuvimab-zykl) for injection, approved on December 21, 2020, manufactured by Ridgeback Biotherapeutics, LP, meets the criteria for a material threat MCM priority review voucher.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/04/23/2025-06970/issuance-of-priority-review-voucher-material-threat-medical-countermeasure-product-ebanga)
- API: https://www.federalregister.gov/api/v1/documents/2025-06970

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
